| Today’s Big NewsFeb 6, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now.
|
|
| By Nick Paul Taylor Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity candidates as part of its quarterly clear-out. Besides those cuts, the company removed eczema and heart failure prospects from its pipeline. |
|
|
|
By Nick Paul Taylor,James Waldron AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as the drugmaker reevaluated the worth of its Alexion acquisition. The drugmaker took another charge in relation to last year’s $2 billion push into radiopharmaceuticals. |
By Gabrielle Masson Pfizer is laying down new pieces for its leadership team structure, selecting Jeffrey Legos, Ph.D., to replace interim Chief Oncology Officer Roger Dansey, M.D. |
By Gabrielle Masson Cancer biotech Viracta Therapeutics has closed its doors, laying off all employees and winding down operations. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By James Waldron X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor. |
By James Waldron Kura Oncology and Kyowa Kirin claim to have scored a phase 2 win for their oral leukemia treatment while reassuring analysts about the lack of hard data to prove it. |
By Kevin Dunleavy Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money. |
By Conor Hale Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to live under the skin for as long as three years. |
By Kevin Dunleavy With a $2.2 billion settlement, GSK has resolved most of its Zantac litigation. But now it faces a proposed class-action lawsuit for allegedly deceiving investors about its knowledge of a potential carcinogen in the heartburn medicine. |
Fierce podcastsDon’t miss an episode |
| | As the first two weeks of his second term showed, keeping up with Trump’s actions—and their ramifications—requires full-time focus. A policy expert breaks down how Congress might approach reform in 2025. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
